Compare MRAM & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRAM | TTRX |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.8M | 298.8M |
| IPO Year | 2016 | 2025 |
| Metric | MRAM | TTRX |
|---|---|---|
| Price | $16.37 | $9.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $18.50 | $8.00 |
| AVG Volume (30 Days) | ★ 1.1M | 48.7K |
| Earning Date | 04-29-2026 | 05-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $49,417,000.00 | N/A |
| Revenue This Year | $10.22 | N/A |
| Revenue Next Year | $7.38 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.51 | N/A |
| 52 Week Low | $6.81 | $2.57 |
| 52 Week High | $51.50 | $11.69 |
| Indicator | MRAM | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.42 | 58.87 |
| Support Level | $15.90 | $9.04 |
| Resistance Level | $16.74 | $10.72 |
| Average True Range (ATR) | 1.18 | 0.69 |
| MACD | -0.12 | -0.04 |
| Stochastic Oscillator | 13.19 | 85.05 |
Everspin Technologies Inc is a manufacturer of Magnetoresistive Random Access Memory (MRAM) technology. The company manufactures MRAM products using both captive and third-party manufacturing capabilities. It purchases industry-standard complementary metal-oxide semiconductor (CMOS) wafers from semiconductor foundries and perform back end of line (BEOL) processing that includes magnetic-bit technology at leased 200mm fabrication facility in Chandler, Arizona. It also manufactures full-flow 300mm CMOS wafers with STT-MRAM magnetic-bit technology integrated in BEOL. The company's customers are in key markets, such as industrial, medical, automotive/transportation, aerospace, and data center.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.